Ligand Pharmaceuticals Incorporated (LGND)

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Reviewing Omeros (NASDAQ:OMER) & Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital

Ligand to Participate in September Investor Conferences

Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Arrowstreet Capital Limited Partnership

Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

XOMA Royalty Announces Closing of Its Acquisition by Ligand

5 Stock Setups Where Wall Street Sees the Most Upside Right Now